<DOC>
	<DOCNO>NCT00021294</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development recurrence cancer . Eflornithine without triamcinolone may effective prevent nonmelanoma skin cancer . PURPOSE : Randomized phase II trial compare effectiveness eflornithine without triamcinolone prevent nonmelanoma skin cancer patient actinic keratosis .</brief_summary>
	<brief_title>Eflornithine With Without Triamcinolone Preventing Nonmelanoma Skin Cancer Patients With Actinic Keratosis</brief_title>
	<detailed_description>OBJECTIVES : I . Compare safety efficacy eflornithine ( DFMO ) v placebo chemoprevention non-melanoma skin cancer patient moderate heavy actinic keratosis ( AK ) . II . Determine whether drug revers AK patient . III . Determine whether triamcinolone reduce DFMO-induced skin irritation patient . OUTLINE : This randomize , double-blind , placebo-controlled study . Patients randomize 1 4 treatment arm . Arm I : Patients receive eflornithine ( DFMO ) topically triamcinolone topically forearms daily . Arm II : Patients receive DFMO placebo topically arm I . Arm III : Patients receive placebo triamcinolone topically arm I . Arm IV : Patients receive 2 placebo topically arm I . Treatment continue 6 month absence unacceptable toxicity . Patients follow 2 week . PROJECTED ACCRUAL : A total 150 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<mesh_term>Eflornithine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis actinic keratosis At least 3 clinically visible lesion low posterior forearm Lesions must discrete quantifiable No prior concurrent skin cancer forearm Prior skin cancer ( melanoma ) area forearm allow unless chronic recurrent lesion indicate immunosuppression Concurrent skin cancer area forearm allow active lesion previously excise PATIENT CHARACTERISTICS : Age : 18 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No serious concurrent illness No immunosuppression due medication disease No invasive cancer ( include melanoma ) within past 5 year Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 28 day prior study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 5 year since prior systemic chemotherapy At least 6 month since prior fluorouracil ( 5FU ) forearm Prior concurrent 5FU face allow Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : See Disease Characteristics Other : At least 30 day since prior megadoses vitamin ( e.g. , 400 IU vitamin E , 200 microgram selenium , 1 g vitamin C per day tolerable upper limit supplement ) At least 6 month since prior tretinoin forearm Prior concurrent tretinoin face allow No concurrent megadoses vitamins No concurrent investigational drug device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2002</verification_date>
	<keyword>basal cell carcinoma skin</keyword>
	<keyword>squamous cell carcinoma skin</keyword>
	<keyword>actinic keratosis</keyword>
</DOC>